Funded Tech Companies

Immutrin

Based in Cambridge, Immutrin is venture-backed, with investment from SR One Capital Management, Cambridge Innovation Capital and Frazier Life Sciences.

Company Overview

Contact Information

Company Background Information

Overview

Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company's lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

3/24/2026

Financing History

Management Team

Title

Name

Email & Social

Chairman

Sef Kurstjens

        

Chief Executive Officer

Mihriban Tuna

        

Chief Financial Officer

Tolga Hassan

        

Co-Founder

Daniel Christ

        

Co-Founder

Mark Pepys

        

Co-Founder

Gregory Winter

        

VP - R & D

Kin Leung

        

Company Investors

• SR One Capital Management
• Cambridge Innovation Capital
• Frazier Life Sciences (James Topper)
• F-Prime Capital
• Qiming Venture Partners USA
• Cambridge Enterprise

Browse more funded tech companies:

Immuto Scientific | imo.im

Share this article

About Our VC Deals Database

This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary